- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
The House Oversight & Reform Committee is already probing the Trump administration’s national drug strategy that was released Monday (Feb. 4), continuing the work of the late Chair Elijah Cummings (D-MD) who last year questioned the White House Office of National Drug Control Policy (ONDCP) on what he called an inadequate strategy.
Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.
Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.
© 2002-2025. Inside Washington Publishers | Contact Us